Chronic Skin Ulcers & Infected Chronic Skin Ulcers
Chronic ulcers in the form of venous leg ulcers and diabetic ulcers are a worldwide problem to the great inconvenience of the affected patients.
There are several categories of non-healing wounds and ulcers, each of which has its own specialised treatment. These treatments include debridement of necrotic tissue, infection control and local wound care. However, non-healing wounds and ulcers have in common that they are typically caused by a deficiency in local blood supply, which fails to provide the nutritional means of keeping the cells involved in healing fully active. White blood cells (neutrophils) and macrophages fail in their housekeeping functions, and the macrophages fail to provide their normal stimulation of repair functions. Reponex has several programs running which are addressing various approaches to non-healing wounds.
Rationale for developing treatment for wound healing
Chronic skin wounds are typically associated with diabetes, venous insufficiency, local pressure or ischemia. Common to these is a lack of local blood supply, which impairs the provision of the substances that are necessary to maintain full activity of the cells involved in the healing process. The white blood cells and macrophages do not perform their functions adequately, and the macrophages do not stimulate the healing processes as they normally would. By treating chronic wounds with Reponex main API, the cleansing functions of the neutrophils and macrophages are restored, so that the macrophages can once again control the repair processes and accelerate healing.
Combination with other healing-promoting agents, RNX-022
Bacteria are present in all chronic wounds, but more than 16% of the wounds may in certain stages be more aggressively infected by pathogenic bacteria such as Staph. aureus and/or P. aeruginosa. On its own, Reponex main API can strengthen the local defense against bacterial infection by its action on neutrophils and macrophages, but the elimination of bacteria is accelerated if a high local concentration of an effective antibiotic is supplied as well. Reponex preferred antibiotic is particularly suitable since its broad spectrum covers most of the relevant pathogenic organisms, including methicillin-resistant S. aureus (MRSA), multidrug-resistant bacteria and many common strains of P. Aeruginosa. At the same time, it is remarkably non-toxic to the patient and the effector cells, the neutrophils and macrophages, involved in healing. If bacterial culture from the wound detects special cases of organisms that are relatively insensitive to Reponex preferred antibiotic, combinations containing a second antibiotic may be employed. Some believe that the use of topical antibiotics for wound treatment may have unfavourable consequences in the form of the rapid development of bacterial resistance to the antibiotic that will make further treatment less effective and can generate yet another resistant strain that can be transmitted to other people. It is not expected to apply to the local use of Reponex preferred antibiotic, which will be applied at a high local concentration. If any bacterial resistance is developed, this will be due to the suppression of a biochemical mechanism in the bacterium itself, which leads to a weakening of the organism’s virulence and viability. The widespread use of antibiotics in other countries has not led to an increased prevalence of resistant strains in the population.
Combination with antibiotics for treatment of infected chronic skin ulcers, RNX-023
Combining with antibiotics, RNX-023 is a unique powdered formulation that possesses exceptional advantages when addressing chronic wounds. In these wounds, bacteria are invariably present, with approximately 16% potentially reaching more aggressive infection stages involving pathogenic bacteria like Staphylococcus aureus and Pseudomonas aeruginosa. RNX-023, as a powder, offers distinct benefits over creams or gels due to its enhanced ability to attach itself to infected wounds, especially those with excessive exudation.
RNX-023’s primary active ingredient independently reinforces the local defense against bacterial infections by enhancing the action of neutrophils and macrophages. However, the elimination of bacteria is expedited when a high local concentration of an effective antibiotic is introduced. The preferred antibiotic in Reponex’s arsenal is particularly well-suited due to its broad-spectrum coverage, effectively combating a wide array of relevant pathogenic organisms, including challenging strains such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant bacteria, and common Pseudomonas aeruginosa strains. Remarkably, this antibiotic demonstrates low toxicity to both patients and the essential effector cells involved in the healing process.
